GoFast CAR T-cell therapy for recurrent large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy called GoFast CAR T-cell therapy for people with large B-cell lymphoma that has not responded to treatment or has returned. It uses your own immune cells to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of lymphoma called large B-cell lymphoma that did not respond to treatment or came back.
- Your lymphoma cells have a marker called CD19 (confirmed by a lab test).
- You are generally well enough to carry out daily activities (ECOG 0-2 or KPS > 80).
- You do not have active infections like hepatitis B, hepatitis C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hear when a new Relapsed or Refractory Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.